Mednet Logo

In a patient with multiple myeloma who cannot tolerate lenalidomide or bortezomib due to GI toxicity, what regimen would you choose for next-line therapy?

Is there evidence for daratumumab-based doublet regimens? Would your choice differ based on the patient's transplant eligibility?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · OhioHealth
Answered on

Often, lowering the dose of lenalidomide and/or bortezomib does help. If the patient absolutely cannot tolerate at any dose levels, then I would do Daratumumab based therapy. Start with Daratumumab/dex; if it's tolerable, one can add pomalidomide. Intolerance to lenalidomide does not mean intoleranc...

Join for free or sign in to see the full answer